[go: up one dir, main page]

DK1125929T3 - Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester - Google Patents

Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester

Info

Publication number
DK1125929T3
DK1125929T3 DK00310064T DK00310064T DK1125929T3 DK 1125929 T3 DK1125929 T3 DK 1125929T3 DK 00310064 T DK00310064 T DK 00310064T DK 00310064 T DK00310064 T DK 00310064T DK 1125929 T3 DK1125929 T3 DK 1125929T3
Authority
DK
Denmark
Prior art keywords
trifluoromethyl
methoxycarbonylamino
quinoline
dihydro
benzyl
Prior art date
Application number
DK00310064T
Other languages
Danish (da)
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1125929T3 publication Critical patent/DK1125929T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00310064T 1999-11-30 2000-11-13 Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester DK1125929T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
DK1125929T3 true DK1125929T3 (da) 2006-04-03

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00310064T DK1125929T3 (da) 1999-11-30 2000-11-13 Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester

Country Status (45)

Country Link
US (1) US6313142B1 (es)
EP (1) EP1125929B1 (es)
JP (1) JP3579345B2 (es)
KR (1) KR100408177B1 (es)
CN (1) CN1173953C (es)
AP (1) AP2000002011A0 (es)
AR (1) AR029775A1 (es)
AT (1) ATE315028T1 (es)
AU (1) AU784694B2 (es)
BG (1) BG105009A (es)
BR (1) BR0005636A (es)
CA (1) CA2327029C (es)
CO (1) CO5261552A1 (es)
CY (1) CY1104989T1 (es)
CZ (1) CZ20004407A3 (es)
DE (1) DE60025317T2 (es)
DK (1) DK1125929T3 (es)
DZ (1) DZ3079A1 (es)
EA (1) EA003668B1 (es)
EE (1) EE200000659A (es)
ES (1) ES2254109T3 (es)
GE (1) GEP20022798B (es)
GT (1) GT200000190A (es)
HK (1) HK1038007A1 (es)
HN (1) HN2000000203A (es)
HR (1) HRP20000804A2 (es)
HU (1) HUP0004747A3 (es)
ID (1) ID28489A (es)
IL (1) IL139849A (es)
IS (1) IS5715A (es)
MA (1) MA25223A1 (es)
NO (1) NO20006039L (es)
NZ (1) NZ508509A (es)
OA (1) OA11494A (es)
PA (1) PA8503801A1 (es)
PE (1) PE20010913A1 (es)
PL (1) PL344208A1 (es)
SG (1) SG102603A1 (es)
SK (1) SK17792000A3 (es)
TN (1) TNSN00230A1 (es)
TW (1) TW591016B (es)
UA (1) UA65615C2 (es)
UY (1) UY26451A1 (es)
YU (1) YU71500A (es)
ZA (1) ZA200006947B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MXPA04005864A (es) * 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
US7279297B2 (en) * 2002-04-11 2007-10-09 Roar Holding Llc Ex vivo method for determination of CETP activity and efficacy of heart disease treatment
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US7223870B2 (en) * 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
WO2004056358A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1601655A2 (en) * 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
WO2004082593A2 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Pharmaceutical compositions of cetp inhibitors
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EA200600737A1 (ru) * 2003-10-08 2006-10-27 Эли Лилли Энд Компани Соединения и способы для лечения дислипидемии
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MXPA06014716A (es) * 2004-06-24 2007-03-12 Lilly Co Eli Compuestos y metodos para el tratamiento de dislipidemia.
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
UA90706C2 (ru) * 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
IL317973A (en) 2022-07-05 2025-02-01 Newamsterdam Pharma B V Salts of ovicetrapib and processes for their production and intermediates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (es) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
JP3579345B2 (ja) 2004-10-20
OA11494A (en) 2004-05-07
ES2254109T3 (es) 2006-06-16
EE200000659A (et) 2001-08-15
EP1125929B1 (en) 2006-01-04
NZ508509A (en) 2001-06-29
SK17792000A3 (sk) 2002-10-08
BR0005636A (pt) 2001-07-17
IS5715A (is) 2001-05-31
PE20010913A1 (es) 2001-09-10
EA200001129A2 (ru) 2001-06-25
KR100408177B1 (ko) 2003-12-01
CZ20004407A3 (cs) 2002-06-12
HRP20000804A2 (en) 2001-06-30
HN2000000203A (es) 2001-06-13
NO20006039D0 (no) 2000-11-29
MA25223A1 (fr) 2001-07-02
AU784694B2 (en) 2006-06-01
US6313142B1 (en) 2001-11-06
NO20006039L (no) 2001-05-31
TNSN00230A1 (fr) 2005-11-10
HUP0004747A2 (hu) 2001-10-28
CY1104989T1 (el) 2010-03-03
CN1173953C (zh) 2004-11-03
PA8503801A1 (es) 2002-07-30
DZ3079A1 (fr) 2004-10-24
JP2001163859A (ja) 2001-06-19
DE60025317D1 (de) 2006-03-30
KR20010052012A (ko) 2001-06-25
CA2327029A1 (en) 2001-05-30
BG105009A (en) 2001-11-30
CO5261552A1 (es) 2003-03-31
CN1302800A (zh) 2001-07-11
AR029775A1 (es) 2003-07-16
IL139849A (en) 2006-10-31
TW591016B (en) 2004-06-11
AU7178900A (en) 2001-05-31
DE60025317T2 (de) 2006-08-03
EA200001129A3 (ru) 2001-10-22
SG102603A1 (en) 2004-03-26
EA003668B1 (ru) 2003-08-28
YU71500A (sh) 2003-02-28
UY26451A1 (es) 2001-06-29
PL344208A1 (en) 2001-06-04
ATE315028T1 (de) 2006-02-15
CA2327029C (en) 2005-08-09
HUP0004747A3 (en) 2002-12-28
ZA200006947B (en) 2002-05-27
AP2000002011A0 (en) 2000-12-31
GEP20022798B (en) 2002-09-25
UA65615C2 (uk) 2004-04-15
HU0004747D0 (es) 2001-02-28
HK1038007A1 (en) 2002-03-01
EP1125929A1 (en) 2001-08-22
GT200000190A (es) 2002-04-27
ID28489A (id) 2001-05-31
IL139849A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
DK1125929T3 (da) Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester
CA2473991A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
TR199900428T2 (xx) 1,4-Heterosiklik metaloproteaz inhibit�rleri.
TR199900383T2 (xx) 1,3-Diheterosiklik metaloproteaz inhibit�rleri.
DE60000708D1 (de) Verfahren zur Herstellung von (Meth)acrylsäure
TR199900382T2 (xx) Heterosiklik metaloproteaz inhibit�rleri.
EE200200365A (et) (RR,SS)-3-(2-dimetüülaminometüül-1-hüdroksütsükloheksüül)fenüül-2-hüdroksübens oaadist tulenevad estrid
DE60021308D1 (de) Verfahren zur Herstellung von (Meth)acrylsäure
TR199900429T2 (xx) Spirosiklik metaloproteaz inhibit�rleri.
TR199800669A3 (tr) Akrilonitrilin polimerizasyonu için islem
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
TR200000720T2 (tr) Kuinolin türevlerinin sentezi için metod.
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DE60001599D1 (de) Verfahren zur Herstellung von cis-1-2-[4-(6-Methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl-pyrrolidin
DK0871616T3 (da) Fremgangsmåde til fremstilling af lægemidler mod malaria
DE69907865D1 (de) Verfahren zu Herstellung von 3-Alkyl-3-Hydroxymethyloxetanen
DE60043610D1 (de) Verfahren zur herstellung von l-lysin
NO20021727L (no) Fremgangsmåte for fremstilling av 3,4-metylen-dioksy- mandelisk syre
DE60221500D1 (de) Verfahren zur herstellung von fibraten
NO20016390D0 (no) Fremgangsmåte for fremstilling av (-)-(1S,4R) N-beskyttede 4- amino-2-cyklopenten-1-karboksylatestere
DE50100478D1 (de) Verfahren zur Herstellung von Esterquats
MY134349A (en) Preparation of anhydrous cetp inhibitor
NO20002944D0 (no) FremgangsmÕte for fremstilling av isopropylmetyl-(2-)3-n- propolsyfenoksy)etyl)amin
DK0884299T3 (da) Fremgangsmåde til fremstilling af 3,3-dimethylsmørsyre